Hopp til innhold
NHI.no
Annonse

Leverkreft, primær: Behandling

Innhold i artikkelen

Hepatocellulært karsinom er vanskelig å behandle fordi de aller fleste tilfeller oppdages først når kreftsykdommen er utbredt, eller det foreligger betydelig nedsatt leverfunksjon. Men som ved andre kreftsykdommer, gir tidlig diagnose bedre muligheter for overlevelse. De mest aktuelle behandlingsmetodene er å fjerne den syke delen av leveren (leverreseksjon), eventuelt utføre levertransplantasjon eller lokalbehandling med f.eks. blokkering av blodtilførselen til svulsten eller stråler. Siden det er stor mangel på givere av lever, er levertransplantasjon sjelden aktuelt. Lokalbehandling har kun en lindrende effekt.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Hepatocellulært karsinom . Referanselisten for dette dokumentet vises nedenfor

  1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245. PubMed
  2. Schwartz JM, Carithers RL, Sirlin CB. Clinical features and diagnosis of primary hepatocellular carcinoma. UpToDate, last updated Mar 29, 2021. UpToDate
  3. Cicalese L. Hepatocellular carcinoma. Medscape, last updated May 03, 2017. emedicine.medscape.com
  4. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018; 29 (Suppl._4): iv238–iv255. www.esmo.org
  5. Schwartz JM, Carithers RL. Epidemiology and risk factors for hepatocellular carcinoma. UpToDate, last updated Oct 13, 2020. www.uptodate.com
  6. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69. PubMed
  7. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016; 122:1312. PubMed
  8. Kreftregisteret. Cancer in Norway 2020. Oslo, 2021: www.kreftregisteret.no.
  9. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007 Feb. 11(1):191-207, x-xi.
  10. Yatsuji S, Hashimoto E, Tobari M et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248–254. PMID: 19032450 PubMed
  11. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. Journal of the American Medical Association
  12. Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9:161. PubMed
  13. Crippin JS. Biopsy of suspicious liver nodules: does it change management?. Clin Gastroenterol Hepatol 2006; 4: 361. PubMed
  14. Abdalla EK, Stuart KE. Overview of treatment approaches for hepatocellular carcinoma. UpToDate, last updated Nov 29, 2021. UpToDate
  15. Llovet JM, Mazzaferro V, Hilgard P, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. doi:10.1056/NEJMoa0708857 DOI
  16. Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD006935. DOI: 10.1002/14651858.CD006935.pub2. DOI
  17. Awad T, Thorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD007611. DOI: 10.1002/14651858.CD007611.pub2. DOI
  18. Zhong JH, Li LQ, Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD008713. DOI: 10.1002/14651858.CD008713.pub2. DOI
  19. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD004787. DOI: 10.1002/14651858.CD004787.pub2. DOI
  20. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208. PubMed
Annonse
Annonse